Monday, March 27, 2023

Time: 10:00-11:00 AM EST

As trial sponsors lean into incorporating the FDA’s guidance on diversity, equity, and inclusion (DEI) in their rare disease clinical research, disability should be part of those plans and initiatives. This panel will explore the intersectionality of people who live with a rare disease, disability, and other important lived experiences. Discussions will also explore how patient advocates, CROs, pharma companies, researchers, and other key stakeholders can better engage, include, and incorporate insights from people who live within that intersectionality of experiences into improved clinical trial research and development.


Kendall Davis,

Director, Advocacy Strategy, Center for Rare Diseases, ICON plc


Erika Heiges

Senior Engagement Strategy Lead, Clinical Trial Engagement & Enrollment & DAWN DDiCT Team Lead, Bristol Myers Squibb

Dr. James Huang

Director of Student Health Services, Gallaudet University

Amir Rahimi

Senior Manager, Product Communications and Public Affairs, Janssen Pharmaceuticals

Angela Rochelle

Head of Healthcare Diversity Initiatives, Langland

Grayson Schultz

Writer, activist, and educator